International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 036-040
THE COMPARISION OF EPIRUBICIN ONLY AND EPIRUBICIN PLUS ESTRAMUSTINE PHOSPHATE TREATMENTS IN HORMONE RESISTANT PROSTATE CANCER (HRPC) PATIENTS
AHMET KİPER1, ORHAN YİĞİTBAŞI1, M. ABDURRAHİM İMAMOĞLU1, İSMAİL GÜL1
SSK Ankara Eğitim Hastanesi l. Üroloji Kliniği, ANKARA
Keywords: prostate cancer, epirubicin, and estramustine phosphate
In the first HRPC patient group, we used epirubicine 30 mg/m2 weekly per 8 week than monthly per 4-6 months. In the second group, addition to the epirubicine dosage we used estramustine phosphate 1600 mg/day as a combined therapy. Both of the groups were compared in subjective response and side effects. At the end of 3rd month the subjective response were cured in a row 96% and 100% in the groups. And then these responses would become to increase nearly at the 6th month in the monotherapy group and at the 8.4th month in the second group. Mean survival time was 15.8 month in monotherapy group and 13.7 month in combined therapy group (p>0.5). We observed the myelosupressive effect as 21% and 17% in a row. In the 35% of the patients in the combined therapy group, we stopped the therapy because of the severe gastrointestinal complaints. Also in this group, two exitus occurred because of the cardiotoxic side effects. As we saw no difference between the groups in subjective answers and mean survival time, we watched more side effects in the combined therapy group. As a conclusion we decided that epirubicine, as a monotherapeutic agent, was effective in HRPC patients
AHMET KİPER1, ORHAN YİĞİTBAŞI1, M. ABDURRAHİM İMAMOĞLU1, İSMAİL GÜL1
SSK Ankara Eğitim Hastanesi l. Üroloji Kliniği, ANKARA
Keywords: prostate cancer, epirubicin, and estramustine phosphate
In the first HRPC patient group, we used epirubicine 30 mg/m2 weekly per 8 week than monthly per 4-6 months. In the second group, addition to the epirubicine dosage we used estramustine phosphate 1600 mg/day as a combined therapy. Both of the groups were compared in subjective response and side effects. At the end of 3rd month the subjective response were cured in a row 96% and 100% in the groups. And then these responses would become to increase nearly at the 6th month in the monotherapy group and at the 8.4th month in the second group. Mean survival time was 15.8 month in monotherapy group and 13.7 month in combined therapy group (p>0.5). We observed the myelosupressive effect as 21% and 17% in a row. In the 35% of the patients in the combined therapy group, we stopped the therapy because of the severe gastrointestinal complaints. Also in this group, two exitus occurred because of the cardiotoxic side effects. As we saw no difference between the groups in subjective answers and mean survival time, we watched more side effects in the combined therapy group. As a conclusion we decided that epirubicine, as a monotherapeutic agent, was effective in HRPC patients